预防性葡萄糖凝胶对新生儿血糖连续监测指标的影响:Pre-hPOD试验二次分析
该二次分析纳入133名有低血糖风险的新生儿,在生后48小时使用连续葡萄糖监测评估不同剂量预防性葡萄糖凝胶对血糖稳定性的影响。结果显示低血糖常见,68%经连续监测检出;预防性葡萄糖凝胶可降低低血糖风险且不增加严重或反复低血糖事件。
要点
- 有低血糖风险新生儿中连续监测检出低血糖比例高于血糖监测。
- 预防性葡萄糖凝胶可能与降低低血糖风险相关,尤其单次200 mg/kg剂量。
- 葡萄糖凝胶未增加反复或严重低血糖事件及峰值血糖。
核心结论
- 在有低血糖风险的新生儿中,预防性葡萄糖凝胶可降低低血糖风险,且对血糖稳定性无不良影响。
研究设计与样本
- pre-hPOD随机剂量试验的二次分析,纳入133名有低血糖风险的新生儿,生后48小时进行连续葡萄糖监测。
主要发现
- 血糖监测检出41%婴儿低血糖,连续间质葡萄糖监测检出68%。
- 生后48小时低间质葡萄糖浓度平均持续时间为295±351分钟。
- 接受任何剂量葡萄糖凝胶的婴儿发生低血糖(<47 mg/dL [2.6 mmol/L])的风险低于安慰剂组(P = .08),单次200 mg/kg剂量组相对风险为0.70(95% CI, 0.50-0.10; P = .049)。
- 葡萄糖凝胶组处于54-72 mg/dL(3-4 mmol/L)中心血糖范围的时间比例更高(任何剂量组58.2±20.3% vs 安慰剂组50.0±21.9%;平均差8.20%;95% CI, 0.43-15.9%;P = .038)。
- 葡萄糖凝胶未增加反复或严重低血糖事件,也未增加峰值血糖浓度。
关键数值与推荐
- 低血糖定义采用<47 mg/dL(2.6 mmol/L);中心血糖范围定义为54-72 mg/dL(3-4 mmol/L)。
- 单次200 mg/kg葡萄糖凝胶组相对风险0.70(95% CI, 0.50-0.10; P = .049)。
- 任何剂量组中心血糖范围时间比例平均差8.20%(95% CI, 0.43-15.9%; P = .038)。
临床怎么用
- 对于有低血糖风险的新生儿,可考虑预防性使用葡萄糖凝胶以降低低血糖风险。
- 连续葡萄糖监测可发现血糖监测未检出的低血糖,但需结合临床解读。
局限性
- 本文为二次分析,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effects of different doses of prophylactic dextrose gel on glycemic stability assessed using continuous glucose monitoring in the first 48 hours when given to babies at risk of neonatal hypoglycemia. STUDY DESIGN: Continuous glucose monitoring was undertaken for the first 48 hours in 133 infants at risk of hypoglycemia who participated in the pre-hPOD randomized dosage trial of dextrose gel prophylaxis. RESULTS: Low glucose concentrations were detected in 41% of infants by blood glucose monitoring and 68% by continuous interstitial glucose monitoring. The mean ± SD duration of low interstitial glucose concentrations was 295 ± 351 minutes in the first 48 hours. Infants who received any dose of dextrose gel seemed to be less likely than those who received placebo gel to experience low glucose concentrations (<47 mg/dL [2.6 mmol/L]; P = .08), particularly if they received a single dose of 200 mg/kg (relative risk, 0.70; 95% CI, 0.50-0.10; P = .049). They also spent a greater proportion of time in the central glucose concentration range of 54-72 mg/dL (3-4 mmol/L) (any dose, mean ± SD, 58.2 ± 20.3%; placebo, 50.0 ± 21.9%; mean difference, 8.20%; 95% CI, 0.43-15.9%; P = .038). Dextrose gel did not increase recurrent or severe episodes of low glucose concentrations and did not increase the peak glucose concentration. These effects were similar for all trial dosages. CONCLUSIONS: Low glucose concentrations were common in infants at risk of hypoglycemia despite blood glucose monitoring and treatment. Prophylactic dextrose gel reduced the risk of hypoglycemia without adverse effects on glucose stability.
引用
- Hegarty JE, Alsweiler JM, Gamble GG, et al. Effect of Prophylactic Dextrose Gel on Continuous Measures of Neonatal Glycemia: Secondary Analysis of the Pre-hPOD Trial. J Pediatr. 2021. PMID: 33798509. doi:10.1016/j.jpeds.2021.03.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。